• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Blogs » The Carlat Psychiatry Blog » Tips on the Doubts about Ketamine/Esketamine

The Carlat Psychiatry Blog
The Carlat Psychiatry Blog RSS FeedRSS

Tips on the Doubts about Ketamine/Esketamine

August 19, 2020
Ketamine and esketamine have been shown to provide rapid relief of suicidality, however, many lingering doubts have been raised about these medicines. In a previous article from The Carlat Psychiatry Report, Nolan Williams, M.D., discusses the potential negative consequences of ketamine/esketamine treatment. Here are some of Dr. Williams’s tips:

It might have an abuse liability. “There have been cases where patients get exposed to ketamine in an office setting and then start to order it off the internet” (Study Link). “However, ketamine has some promising data as a treatment for addictions, like cocaine and alcohol (Study Link)”. 

Discontinuation may increase suicidality. There were 6 deaths in FDA-registration studies, but it was not statistically significant, therefore, the drug was ultimately approved. “Three of them were definite suicides, and these suicides occurred after their last esketamine dose (Link)”. “Furthermore, the patients who died by suicide had no signs of suicidality in detailed assessments done during the study, which suggests it may have come on during the withdrawal period”.

You need more to prevent a depressive relapse. “So far the only thing that works is more ketamine/esketamine, which raises questions about potential tolerance, withdrawal, and addiction”. Regardless, more studies are needed to determine if these problematic outcomes are due to prolonged ketamine/esketamine treatment.

Abuse can cause bladder inflammation and nerve fibrosis. Ketamine abuse appears to cause “cellular death in the bladder and fibrotic changes in nerves”. This is a significant problem considering that approximately 50% of ketamine abusers are affected (Link). 

Cognitive and neurodegenerative problems. “Long-term ketamine abuse has been associated with cognitive problems and loss of brain tissue in the frontal lobes and left temporoparietal regions (Liao Y et al, Brain 2010;133(7):2115–2122)”. However, ketamine/esketamine may potentially elicit neurotoxic or neuroprotective effects which are believed to be dose-dependent. 

Want to learn more about ketamine/esketamine treatment including the current research being done to address these problematic factors and the known benefits of this treatment? Click Here. Not a subscriber yet? Subscribe now.
Carlat Total Access Subscriptions: Get access to every article on the website.

Complete access to every article you search on the website.

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • HospPsychiatry_Spiral_Binding_Sm.png

    Hospital Psychiatry Fact Book, First Edition (2025) - Spiral Bound

    This comprehensive guide is designed to be a valuable resource for professionals working in...
    READ MORE
Featured Video
  • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
    General Psychiatry

    KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

    Read More
Featured Podcast
  • shutterstock_2622607431.jpg
    General Psychiatry

    Should You Test MTHFR?

    MTHFR is a...
    Listen now
Recommended
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report
  • The Carlat Psychotherapy Report

Contact

carlat@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.